UK markets close in 57 minutes
  • FTSE 100

    7,801.37
    +40.26 (+0.52%)
     
  • FTSE 250

    20,502.80
    +604.26 (+3.04%)
     
  • AIM

    885.49
    +12.27 (+1.41%)
     
  • GBP/EUR

    1.1257
    +0.0000 (+0.00%)
     
  • GBP/USD

    1.2286
    -0.0086 (-0.69%)
     
  • BTC-GBP

    19,275.19
    +427.08 (+2.27%)
     
  • CMC Crypto 200

    540.75
    -4.56 (-0.84%)
     
  • S&P 500

    4,172.03
    +52.82 (+1.28%)
     
  • DOW

    33,999.07
    -93.89 (-0.28%)
     
  • CRUDE OIL

    75.13
    -1.28 (-1.68%)
     
  • GOLD FUTURES

    1,941.50
    -1.30 (-0.07%)
     
  • NIKKEI 225

    27,402.05
    +55.17 (+0.20%)
     
  • HANG SENG

    21,958.36
    -113.82 (-0.52%)
     
  • DAX

    15,423.19
    +242.45 (+1.60%)
     
  • CAC 40

    7,143.60
    +66.49 (+0.94%)
     

Market Forecasts for Immuno-Oncology Diagnostics 2023: Outcome Potential and Companion Diagnostics Driving Growth

Company Logo
Company Logo

Dublin, Jan. 16, 2023 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics Including Executive/Consultant Guides and Customized Forecasting/Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.

Diagnostics, companion diagnostics, is driving the success of Immuno-oncology Therapeutics. An entire new segment of the diagnostics industry is being created. And its not a small segment either. It promises to grow dramatically. Histology, genomics and liquid biopsy are converging. A complicated network of pharmaceutical companies, diagnostic companies and instrumentation suppliers are jockeying for position in a new approach to conquering cancer. The approach seems to be working and showing great promise.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

Technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size in this new expanded and comprehensive report.

Key Topics Covered:

1. Market Guides

2. Introduction and Market Definition

3. Immunotherapy - Guide to Immune Technologies
3.1. The Immune System
3.1.1. Innate immune system
3.1.1.1. Surface barriers
3.1.1.2. Inflammation
3.1.1.3. Complement system
3.1.1.4. Cellular barriers
3.1.1.5. Natural killer cells
3.1.2. Adaptive immune system
3.1.2.1. Lymphocytes
3.1.2.2. Killer T cells
3.1.2.3. Helper T cells
3.1.2.4. Gamma delta T cells
3.1.2.5. B lymphocytes and antibodies
3.1.3. Tumor immunology - the immune surveillance system
3.2. Immuno Oncology Diagnostics
3.2.1. Checkpoint Assays
3.2.1.1. Outlook for Checkpoint Assays
3.2.2. Cytokine Assays
3.2.2.1. Outlook for Cytokine Assays
3.2.3. Genomic Germline
3.2.3.1. Outlook for Genomic Germline
3.2.4. Genomic Tumour
3.2.4.1. Outlook for Genomic Tumour
3.2.5. Tumor Microenviroment
3.2.5.1. Outlook for Tumor Microenvironment
3.2.6. Others
3.2.6.1. Outlook for Other Diagnostics

4. Industry Overview

5. Market Trends
5.1. Factors Driving Growth
5.1.1. Outcome potential
5.1.2. Companion Diagnostics
5.1.3. Funding
5.1.4. Technology Environment
5.1.5. Target Solutions
5.2. Factors Limiting Growth
5.2.1. Complex Role of Diagnostics
5.2.2. Clinical Trials Role
5.2.3. Protocols
5.3. Diagnostic Technology Development
5.3.1. Combinations-Issues and Complexity
5.3.2. Shifting Role of Diagnostics
5.3.3. Multiplexing and Foundation One
5.3.4. The Disruption Dynamic
5.3.5. The Race for Biomarkers
5.3.6. The Next Five Years

6. Cancer Immuno-Oncology Diagnostics Recent Developments

7. Profiles of Key Immuno-oncology Companies

8. The Global Market for Immuno-Oncology Diagnostics

9. Global Immuno-Oncology Diagnostic Markets - By Application
9.1. Checkpoint
9.2. Cytokine
9.3. Germline Genetic
9.4. Genetic Tumor
9.5. Tumor Microenvironment
9.6. Other

10. Global Immuno-Oncology Diagnostic Markets - By Technology
10.1. NGS
10.2. PCR
10.3. Fish/IHC
10.4. Chem/IA
10.5. Other Technology

11. Global Immuno-Oncology Diagnostic Markets - By Customer

12. Appendices

Companies Mentioned

  • 10x Genomics, Inc.

  • Abbott Laboratories

  • AccuraGen Inc.

  • Aethlon Medical

  • Agilent/Dako

  • Anchor Dx

  • ANGLE plc

  • AVIVA Systems Biology

  • Baylor Miraca Genetics Laboratories

  • Becton, Dickinson and Company

  • Berkley Lights

  • BGI Genomics Co. Ltd

  • Bioarray Genetics

  • Biocartis

  • Biocept, Inc.

  • Biodesix Inc.

  • BioFluidica

  • BioGenex

  • BioIVT

  • Biolidics Ltd

  • bioMerieux Diagnostics

  • Bioneer Corporation

  • Bio-Rad Laboratories, Inc.

  • Bio-Reference Laboratories

  • Bio-Techne

  • Bioview

  • Bolidics

  • Boreal Genomics

  • Bristol-Myers Squibb

  • Burning Rock

  • Cardiff Oncology

  • Caris Molecular Diagnostics

  • Castle Biosciences, Inc.

  • CellCarta

  • CellMax Life

  • Cepheid (Danaher)

  • Charles River Laboratories

  • Circulogene

  • Cizzle Biotech

  • Clinical Genomics

  • Cytolumina Technologies Corp.

  • Datar Cancer Genetics Limited

  • Diagnologix LLC

  • Diasorin S.p.A.

  • Dxcover

  • Element Biosciences

  • Enzo Biochem

  • Epic Sciences

  • Epigenomics AG

  • Eurofins Scientific

  • Fabric Genomics

  • Fluxion Biosciences

  • Freenome

  • FUJIFILM Wako Diagnostics

  • Fyr Diagnostics

  • GeneFirst Ltd.

  • Genetron Holdings

  • GenomOncology

  • GILUPI Nanomedizin

  • Guardant Health

  • HansaBiomed

  • HeiScreen

  • Helomics

  • HTG Molecular Diagnostics

  • iCellate

  • ICON PLC

  • Illumina

  • Incell Dx

  • Inivata

  • INOVIQ

  • Integrated Diagnostics

  • Invitae Corporation

  • Invivogen

  • Invivoscribe

  • Janssen Diagnostics

  • Lunglife AI Inc

  • MDNA Life SCIENCES, Inc.

  • MDx Health

  • Menarini Silicon Biosystems

  • Mesa Laboratories, Inc.

  • Millipore Sigma

  • Miltenyi Biotec

  • miR Scientific

  • Myriad Genetics/Myriad RBM

  • NantHealth, Inc.

  • Natera

  • NeoGenomics

  • NGeneBio

  • Novogene Bioinformatics Technology Co., Ltd.

  • Oncocyte

  • OncoDNA

  • Ortho Clinical Diagnostics

  • Oxford Nanopore Technologies

  • PamGene

  • Panagene

  • Perkin Elmer

  • Personal Genome Diagnostics

  • Personalis

  • Precipio

  • Precision Medicine Group

  • PrecisionMed

  • Predicine

  • Promega

  • Qiagen

  • Rarecells SAS

  • RareCyte

  • Roche Molecular Diagnostics

  • Screencell

  • Sense Biodetection

  • Siemens Healthineers

  • simfo GmbH

  • Singlera Genomics Inc.

  • Singular Genomics

  • Singulomics

  • SkylineDx

  • Standard BioTools

  • Stilla Technologies

  • Sysmex Inostics

  • Tempus Labs, Inc.

  • Thermo Fisher Scientific Inc.

  • Todos Medical

  • Ultima Genomics

  • Veracyte

  • Volition

  • Vortex Biosciences

For more information about this report visit https://www.researchandmarkets.com/r/rvc54j

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900